Article Text

Download PDFPDF

Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia
Free
  1. Seongseok Yun1,
  2. Faiz Anwer1,
  3. Nicole D Vincelette2
  1. 1Department of Internal Medicine, University of Arizona Medical Center, Tucson, Arizona, USA
  2. 2College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Seongseok Yun, namaska97{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Description

A previously healthy 46-year-old woman presented to the outpatient clinic with chronic general weakness for a month. Physical examination showed splenomegaly and complete blood count showed white cell count 346 000/μL, haemoglobin 11.2 g/dL, platelets 336 000/μL with a differential of neutrophils 21%, bands 32%, lymphocytes 8%, monocytes 5%, promyelocytes 22%, myelocytes 11% and blasts 9%. Subsequent bone marrow biopsy showed cellularity of 100% with marked myeloid hyperplasia and blasts of 21%. Cytogenetics demonstrated BCR-ABL1 translocation confirming the diagnosis of chronic myelogenous leukaemia (CML).1 Imatinib was started as an initial treatment, however the patient developed …

View Full Text